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Abstract
Background: Impulsivity and compulsivity are related to emotional and social maladjustment and often underlie
psychiatric disorders. Recently, alterations in microbiota composition have been shown to have implications for brain
development and social behavior via the microbiota–gut–brain axis. However, the exact mechanisms are not fully
identified. Recent evidence suggests the modulatory effect of synbiotics on gut microbiota and the contribution of
these agents in ameliorating symptoms of many psychiatric diseases. To date, no randomized controlled trial has been
performed to establish the feasibility and efficacy of this intervention targeting the reduction of impulsivity and
compulsivity. We hypothesize that supplementation with synbiotics may be an effective treatment in adults with high
levels of impulsivity and/or compulsivity.
Methods/design: This is a prospective, multicenter, double-blind, randomized controlled trial with two arms: treatment
with a synbiotic formula versus placebo treatment. The primary outcome is the response rate at the end of the placebo-
controlled phase (response defined as a Clinical Global Impression–Improvement Scale score of 1 or 2 = very much
improved or much improved, plus a reduction in the Affective Reactivity Index total score of at least 30% compared with
baseline). A total of 180 participants with highly impulsive behavior and a diagnosis of attention deficit/hyperactivity
disorder (ADHD) and/or borderline personality disorder, aged 18–65 years old, will be screened at three study centers.
Secondary outcome measures, including changes in general psychopathology, ADHD symptoms, neurocognitive
function, somatic parameters, physical activity, nutritional intake, and health-related quality of life, will be explored at
assessments before, during, and at the end of the intervention. The effect of the intervention on genetics, microbiota, and
several blood biomarkers will also be assessed. Gastrointestinal symptoms and somatic complaints will additionally be
explored at 1-week follow-up.
Discussion: This is the first randomized controlled trial to determine the effects of supplementation with synbiotics on
reducing impulsive and compulsive behavior. This clinical trial can contribute to explaining the mechanisms involved in
the crosstalk between the intestinal microbiome and the brain. If effects can be established by reducing impulsive and
compulsive behavior, new cost-effective treatments might become available to these patients.
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Background
Impulsivity may be defined as “a predisposition towards
rapid, unplanned reactions to internal or external stimuli,
with diminished regard to the negative consequences that
such reactions may have for the impulsive individual or
others” [1–4]. In contrast, compulsivity represents “the per-
formance of repetitive and functionally impairing overt or
covert behavior without an adaptive function, performed in
a habitual or stereotyped fashion, either according to rigid
rules or as a means of avoiding perceived negative conse-
quences” [2, 5]. Both traits share neuronal mechanisms in-
volving a dysfunctional inhibition of thoughts and behavior
[1, 6], and, rather than unitary phenomena, they are consid-
ered as multidimensional constructs that involve disruption
within a range of neural processes, including attention,
perception, and coordination of motor and/or cognitive
processes. Impulsive and compulsive symptoms are over-
represented in individuals with several psychiatric disorders,
such as attention-deficit/hyperactivity disorder (ADHD),
borderline personality disorder (BPD), and/or obsessive-
compulsive disorder [7]. Importantly, maladaptive impulsiv-
ity and compulsivity can lead to serious consequences not
only for affected individuals and their families but also for
society. They predispose individuals to aggressive or addict-
ive behaviors, increasing the risk for mortality [8]. Despite
this, data about modifiable risk and protective factors are
largely lacking.
Nutrition, brain, and behavior
Not only heritability, sex, and socioeconomic status (SES)
but also diet may play a pivotal role in impulsive and com-
pulsive symptomatology [9, 10]. In line with this, a num-
ber of studies have shown that different nutrient
combinations may have interactive effects on cognitive
function and behavior, including antioxidants; omega-3
polyunsaturated fatty acids (PUFAs); monounsaturated
fatty acids; polyphenols; potassium; calcium; zinc; fiber;
folate; and/or vitamins A, B12, C, D, or E [11–13]. More
specifically, recent reports have linked aggressive behavior
with low blood omega-3 PUFA levels and/or with low sea-
food consumption [14], and several animal studies have
found that the long-term consumption of a low-calorie
diet enhances autophagy and protects neurons effectively
against aging, maintaining learning and memory capacity,
whereas long-term consumption of a high-calorie diet fa-
cilitates neuronal loss in the hippocampus, aggravating
age-related cognitive impairments [15, 16].
Importantly, the type of food intake can influence
brain development and function in all age groups, with a
recent study showing that prenatal exposure to an un-
healthy diet was associated with ADHD symptoms, fur-
ther linked to altered epigenetic modification of blood-
derived DNA [17, 18]. However, these findings have not
been consistently replicated in large-sample randomized
controlled trials (RCTs), and the underlying mechanisms
remain unknown [19–23].
Gut microbiome, microbiota, and behavior
Although microbiota refers to the specific microorganisms
that are found within a specific environment, microbiome
refers to the collection of genomes from all the microor-
ganisms found in this particular environment [24]. It is hy-
pothesized that an imbalance in the gut microbiota
(dysbiosis) may have a negative effect on neurodevelop-
ment, behavior, and cognition [25–31]. Related to this,
changes in human microbiome and/or microbiota compos-
ition have been consistently found in individuals with aut-
ism spectrum disorder (ASD) [32–36], and a pilot study on
the microbiome has demonstrated, for the first time, a dif-
ference in several bacterial taxa between subjects with
ADHD and healthy control subjects [37]. Specifically, lower
Firmicutes genus and higher Bifidobacterium genus were
found in subjects with ADHD than in healthy individuals,
with the increase in the Bifidobacterium genus relating to
decreased ventral striatal functional magnetic resonance
imagining responses during reward anticipation [37].
The relationship between gut microbiota and the brain
seems to be bidirectional. The gut microbiota modulates
brain function and development, and the brain can alter
the gut microbiota, allowing colonization by pathogenic
bacteria [38–40]. Illustrating this idea, some studies have
shown an overrepresentation of gastrointestinal symp-
toms in patients with both neurodevelopmental and
neuropsychiatric disorders [41–48], and a study in
healthy students found that during exams, psychological
stress increased at the same time that numbers of lacto-
bacilli in stool samples decreased [49].
But how does this bidirectional communication—the
gut–brain axis—work? The “enteric nervous system” is
complex and, regarding neurotransmitters and signaling
molecules, similar to the brain [50]. As an example, 95%
of all circulating serotonin, dopamine, or noradrenaline
precursors are produced by our gut microbiota [50].
This system is connected to the central nervous system
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through hormonal or innate neuronal pathways [51] that
are critical for its development and vice versa [52]. Fur-
thermore, studies have shown that the gut flora is critic-
ally involved in immunoregulation [53–55], whereas
some reports have shown the immune system as an im-
portant regulator of neurodevelopment and synaptic
function in the brain [56]. In line with this, immune dys-
function and/or autoimmunity have been speculated to
be associated with many neuropsychiatric and neurode-
velopmental disorders, such as ADHD [57, 58]. Support-
ing this idea, an increased incidence of immune-
mediated disorders (e.g., asthma, allergic rhinitis, atopic
dermatitis, allergic conjunctivitis, psoriasis, thyrotoxi-
cosis, or type 1 diabetes) has been found among patients
with ADHD [59–62]. Moreover, elevated inflammatory
markers (especially interleukin [IL]-6) [63–65] or auto-
antibody levels (e.g., anti–basal ganglia antibodies, anti-
bodies against the dopamine transporter) [66, 67] have
been found both in serum/plasma and in cerebrospinal
fluid of these patients [63, 68, 69].
Probiotic/synbiotic interventions
Probiotic bacteria, or “probiotics,” are live, nonpatho-
genic microorganisms that normally inhabit the intes-
tines and contribute to the health of the host by
improving microbial balance [70]. On the other hand,
prebiotics are nondigestible ingredients that selectively
stimulate the growth and activity of these probiotic mi-
croorganisms [71]. The synergic combination of probio-
tics and prebiotics is referred to as synbiotics. Recent
findings suggest that probiotics and/or synbiotics can
not only revert dysbiosis but also modulate brain activity
and improve cognition, mood, and behavior [72–78].
Importantly, a recent study has shown that oral adminis-
tration with Lactobacillus during the first 6 months of
life reduced the prevalence of ADHD or ASD at the age
of 13 [79]. However, the exact mechanisms by which
probiotics and/or synbiotics exert their action remain
unknown. Recent findings suggest immunomodulatory
and anti-inflammatory properties of these agents [80],
possibly by selectively targeting T-helper (Th) type 1
[81] and Th17 cell lineages [82].
The aim of the present multicenter, prospective,
double-blind, placebo-controlled, parallel-group study is
to investigate the effect of a synbiotic formula (Synbiotic
2000 Forte 400; Synbiotic AB, Höganäs, Sweden) on re-
ducing impulsive, compulsive, and aggressive behaviors
in a sample of highly impulsive adults with a diagnosis
of attention-deficit/hyperactivity disorder (ADHD) and/
or borderline personality disorder (BPD). In this study,
we will test the idea that supplementation with probio-
tics will, by modifying the gut microbiota structure and
metabolism, reduce impulsive, compulsive, and aggres-
sive behaviors in this specific population and thereby
improve their daily life function. Moreover, we will
evaluate the composition of gut microbiota in this popu-
lation and link it to inflammatory/immunological abnor-
malities that can underlie core symptoms of these
disorders.
Methods/design
This protocol is presented in accordance with the 2013
SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) Statement (See Additional file 1
for the populated SPIRIT Checklist (83).
Trial design and study setting
The Treatment of impulsivity in adults with probiotics
(PROBIA) trial is designed as a 10-week multicenter, pro-
spective, randomized, double-blind, placebo-controlled,
parallel design study. It will be performed in close cooper-
ation between three European clinical centers: Goethe
University Hospital Frankfurt (Department of Psychiatry,
Psychosomatic Medicine and Psychotherapy), Frankfurt,
Germany; Vall d’Hebron Research Institute (Psychiatry,
Mental Health and Addictions Group), Barcelona, Spain;
and Semmelweis University (Department of Psychiatry
and Psychotherapy), Budapest, Hungary. These centers
are all affiliated with or part of university hospitals and,
with around 300 new inpatients and outpatients visiting
each center every year, are considered as reference centers
for the treatment of ADHD, BPD, and other disorders
characterized by high impulsivity levels.
Study population and recruitment
Participants will be eligible for participation in this study
if they meet all the inclusion criteria and none of the ex-
clusion criteria listed in Table 1. With the aim of gender
balancing the study, at least 30% female participants will
be included.
Recruitment began on 22 February 2019 and will have
a duration of 2 years. A total of 180 participants (60
subjects per site) will be recruited by trained psychia-
trists and/or psychologists at the different sites (see Fig.
1). Strategies aimed at optimizing the recruitment
process will include the distribution of handouts or
flyers to colleagues, physicians, and families, as well as
an offer of reimbursement of study-related travel costs
to participants. Furthermore, and depending on local
regulations, information via presentations, websites,
and social media campaigns will be provided. Regular
calls will be made to patients to avoid participant with-
drawal from the study.
Randomization and study intervention
After eligibility checks have been conducted and writ-
ten consent has been obtained by the different psychi-
atrists and/or psychologists of the trial team, eligible
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participants will be randomized to the experimental
(EG) or the control (CG) group in a 1:1 allocation ra-
tio using an independent web-based computerized
service (www.randomization.com). Randomization will
be center-stratified and have a fixed length per center,
being independent of participant characteristics.
However, due to the large sample size, a balanced ra-
tio of baseline characteristics between the EG and CG
is expected.
Individual participant treatment kits will contain all
required daily synbiotic or placebo envelopes for the 10-
week RCT and will be prepared in advance by sequentially
Table 1 Inclusion and exclusion criteria of the PROBIA trial
Inclusion criteria Both males and females aged 18–65 years
A high level of multidimensional impulsivity based on both a Clinical Global Impression–Severity Scale
(CGI-S) score ≥ 4 and an Affective Reactivity Index (ARI) ≥ 5
DSM-5 criteria for attention deficit/hyperactivity disorder (ADHD) and/or borderline personality disorder
(BPD) confirmed by a structured diagnostic interview (ADHD: Diagnostic Interview for Adult ADHD
[DIVA 2.0]; BPD: Structured Clinical Interview for DSM-IV [SCID-II])
Deemed reliable and compliant with the protocol by the investigator
Ability to speak and comprehend the native language of the country in which the assessments take place
Informed consent signed
Exclusion criteria Antibiotherapy within the last 6 weeks prior to study
Currently taking probiotics
Presence of a major psychiatric disorder with psychotic symptoms or other major psychiatric conditions
requiring hospitalization (e.g., significant mood disorders)
Neurological disorders involving central functions (e.g., epilepsy, multiple sclerosis, narcolepsy)
Intelligence quotient (IQ) < 70 (measured by WAIS, if available)
Major physical illnesses of the cardiovascular, endocrine, pulmonal, immune, or gastrointestinal system or
undergoing immunosuppression
History of/present clinically relevant somatic acute or chronic disorders that, in the opinion of the investigator,
might confound the results of tolerability/safety assessments or prohibit the patient from completing the study
or would not be in the best interest of the patient
Documented allergy, hypersensitivity, or intolerance to any of the ingredients of the intervention
Subject has taken another investigational product or taken part in a clinical study within 30 days prior to entering
the study.
Abbreviations: DSM Diagnostic and Statistical Manual of Mental Disorders, PROBIA Treatment of impulsivity in adults with probiotics, WAIS Wechsler Adult
Intelligence Scale
Fig. 1 Timeline of the PROBIA study
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numbering and labeling them as “A” or “B.” Because this
is a double-blind study, neither the participants nor the
clinicians involved in the trial will have access to the
randomization list.
Synbiotic 2000 Forte 400 (SF) is a synbiotic formula cur-
rently produced by Synbiotic AB in Höganäs, Sweden. Each
dose (powder-containing sachet) of SF contains 100 billion
of each of Pediococcus pentosaceus 5-33:3, Lactobacillus
paracasei subsp. paracasei 19, Lactobacillus plantarum
2362, and Leuconostoc mesenteroides 77:1, in combination
with four bioactive fermentable fibers (2.5 g each of β-
glucan, inulin, pectin, and resistant starch). SF is catego-
rized as a generally regarded as safe agent, being tested on
several hundreds of critically ill patients (e.g., pancreatitis,
liver transplant) with no side effects or specific and/or rele-
vant risks conferred to the trial participants [83]. The pla-
cebo (also provided by Synbiotic AB) is composed of the
polysaccharide maltodextrin and has a texture and flavor
similar to SF. Participants will be asked to continue with
their previous medications and/or usual treatments and
add the synbiotic or placebo once daily on top of cold foods
such as yogurt, muesli, or salad. To secure bacterial viabil-
ity, participants will be asked to store both SF and placebo
at + 4–6 °C.
Outcome measures
Primary outcomes
The primary outcome measure will be response to treat-
ment, defined by a reduction in the Affective Reactivity
Index–Self-Report (ARI-S) scale total score of at least
30% compared with baseline plus a Clinical Global Im-
pression–Improvement Scale total score of 1 or 2 (very
much improved or much improved) at the end of the
placebo-controlled phase.
Secondary outcomes
The secondary outcome measures are selected to assess
intervention effects on symptoms of impulsivity, compul-
sivity, and aggression via a series of selected scales and
questionnaires (e.g., the Strengths and Difficulties Ques-
tionnaire, Yale-Brown Obsessive Compulsive Scale, Diffi-
culties in Emotion Regulation Scale, and the Urgency,
Premeditation [lack of], Perseverance [lack of], Sensation
Seeking, Positive Urgency, Impulsive Behavior Scale
[UPPS-P]). Interestingly, the UPPS-P consists of a 59-item
self-report assessing five subscales (negative and positive
urgency, premeditation, perseverance, and sensation seek-
ing), with a mean value being calculated separately for
each scale, allowing the estimation of distinct dimensions
of impulsive behavior [84]. Another secondary outcome
measure will be the change in ADHD symptoms (via the
ADHD Rating Scale [ADHD-RS]). Like the UPPS-P, the
ADHD-RS provides not only a total ADHD score but also
separate scores for inattentive, hyperactive, and impulsive
subscales, providing a better characterization of patients.
Changes in general psychopathology, major stressors,
neurocognitive function, sleep disturbances, body-related
measures (e.g., pulse rate, blood pressure, body mass
index, waist–hip circumference ratio), medications taken,
physical activity (via mobile health application and move-
ment sensors), health-related quality of life, microbiome
composition, and blood markers will also be evaluated.
Blood markers will include genetic parameters, hormones,
neurotransmitters, nutrients, and inflammatory/anti-in-
flammatory molecules (see Table 2).
Blood samples (34.5 ml) will be fractioned into serum
and plasma and stored at − 80 °C. Then, they will be
shipped to the Department of Human Genetics of Rad-
boudumc, Nijmegen, The Netherlands, for storage. There-
after, blood markers will be measured at the Department
of Clinical Biochemistry at Radboudumc in Nijmegen ac-
cording to validated protocols. Participants willing to take
part in the assessment of their microbiome will receive a
specially designed container for feces collection, allowing
participants to send the samples by ordinary post to the
individual centers, where they will be processed and stored
at − 80 °C for later shipping to the Department of Human
Genetics of Radboudumc for sequencing and analysis of
bacterial DNA. Crucially, before and during the interven-
tion, the participants will be asked to send back their fecal
samples within 24 h after the test sessions.
Another secondary outcome measure will be the
change in nutritional intake. Participants will be asked to
complete at least three 24-h dietary recalls (24HDRs): at
baseline, during the intervention, and directly afterward,
including two weekdays and one weekend day on non-
consecutive days. They will need to describe the type
and amount (in grams) of all drinks and foods consumed
during the previous days, starting with the first intake
after waking up in the morning. Moreover, they will
have to specify the time for every meal occasion during
the day (breakfast, lunch, dinner, or snack).
Participant compliance with the intervention (SF or
placebo) will be monitored with the Probabilistic Medi-
cation Adherence Scale throughout the 10 weeks of the
intervention. Moreover, participants will be asked to re-
turn unused envelopes from the previous visit. This will
enable us to secure bacterial viability and at the same
time estimate adherence to treatment. Finally, the pres-
ence of somatic complaints/side effects or gastrointes-
tinal symptoms (via the Bristol Stool Scale) will also be
evaluated.
Participant timeline
The trial timeline is shown in Table 3. Time points per
intervention will be selected on the basis of known dur-
ation to exert effect.
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At the screening visit (TS), the rate of impulsivity will
be established by performing structured interviews, the
ARI-S, and the Clinical Global Impression–Severity
Scale. After having established the presence of high im-
pulsivity, the diagnosis of ADHD and/or BPD will be
assessed via the Diagnostic Interview for Adult ADHD,
Second Edition, and the Structured Clinical Interview
for DSM-IV Axis II Disorders section for BPD, respect-
ively. Thereafter, screening for eligibility based on clin-
ical history, demographics (including SES), tests, and
questionnaires (e.g., Mini-International Neuropsychiatric
Interview [M.I.N.I.-Plus], IQ tests [Wechsler Adult
Intelligence Scale, Fourth Edition]) will be performed,
and informed consent will be obtained. Once this
process is finished, a mobile health system as well as a
food record will be introduced to participants (duration,
approximately 1 h). The mobile health system will enable
patients to share (via a mobile application) data of inter-
est regarding their physical activity (acceleration, num-
ber of steps).
Trial-specific assessments will be done at T0 (dur-
ation, approximately 3 h), scheduled within 1 week
after TS. During the week between TS and the base-
line visit (T0), the mobile health system will be used
at home. Here and during 24 h, participants will wear
movement sensors on two working days and on Sat-
urday and Sunday, and they will be asked to complete
three 24HDRs on a web-based tool or paper on two
nonconsecutive weekdays and one weekend day (dur-
ation, 15 min each). Individuals will also be asked to
collect feces on one day during the 1-week period at
home and to bring it along at T0.
In addition to responding to the questionnaires and
scales listed in Table 1, participants will be instructed on
how to store and eat the study product (SF or placebo).
The intervention will begin on the day after T0, and par-
ticipants will be asked to continue with their usual medi-
cations and/or treatments. Participants will have to
complete another three 24HDRs, collect their feces be-
fore the next visit, and bring it along at T1, following
the same guidelines as during the screening assessments.
T1 (midintervention assessment; duration, approxi-
mately 3 h) will take place 5 weeks after T0. This midin-
tervention assessment aims at obtaining the primary and
secondary outcome measures during the ongoing trial.
Participants will be asked once again to wear movement
sensors, complete another three 24 HDRs, and collect
their feces 1 week before T2 and bring it along at T2. At
10 weeks after initiating the probiotic or placebo interven-
tion (T2), primary and some secondary outcome measures
will be assessed again (duration, approximately 3 h).
Within 1 week after T2 and with the aim of measuring
safety aspects of the intervention (i.e., somatic com-
plaints/side effects as well as gastrointestinal symptoms),
Table 2 Measurement of blood markers
Type of marker Marker name Link with: Tissue
Inflammation TNF-α Inflammation/exercise*/diet Serum/plasma
IL-1β Inflammation/exercise*/diet Serum/plasma
IL-6 Inflammation/exercise*/diet Serum/plasma
CRP Inflammation/diet Serum/plasma
Bacterial lipoprotein Inflammation/diet Serum/plasma
Vitamin B12 Diet Serum/plasma
Folic acid Diet Serum/plasma
Vitamins and minerals Vitamin D Diet Serum/plasma
Iron Diet Serum/plasma
Cu Diet Serum/plasma
Nutrients Cholesterol Diet Serum/plasma
Glucose Diet Serum/plasma
Homocysteine Diet Serum/plasma
BDNF Diet Serum/plasma
5-HT Diet Serum/plasma
Other markers SCFA Diet Feces
GLP-1 Hormone-diet Serum/plasma
Insulin Hormone-diet Serum/plasma
Paraoxonase Diet Serum/plasma
Abbreviations: 5-HT serotonin, BDNF brain-derived neurotrophic factor, CRP C-reactive protein, GLP-1 glucagon-like peptide 1, IL interleukin, SCFA short-chain fatty
acid, TNF-α tumor necrosis factor-α
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Table 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schematic schedule of enrollment,
interventions, and assessments
Study procedures Screening Open label Follow-up
Visit TS T0 T1 T2 T3
Week −1 1 5 10 11
Day −7 to −1 1 35 ± 2 70 ± 2 77 ± 2
Informed consent form X
Inclusion/exclusion criteria X
Demographics (including SES) X
IQ (IQ score based on WAIS, if available) X
M.I.N.I.-Plus assessment X
Confirmation of diagnosis/-es X
Confirmation of ADHD DIVA 2.0 X
Confirmation of BPD SCID-II X
Primary outcome
Clinical Global Impression–Improvement Scale CGI-I X X X
Affective Reactivity Index ARI-S X X X X X
Secondary outcomes
Clinical Global Impression–Severity Scale CGI-S X X X X
Clinician rating of ADHD symptoms ADHD-RS X X X
Self-rating of multidimensional impulsivity UPPS-P X X X
Questionnaire on well-being X X
Functioning Assessment Short Test FAST X X X
Self/other rating of strength and difficulties SDQ X X X
Clinician rating of compulsivity Y-BOCS X X X
Sleep problems 5-item questionnaire X X X
Self-rating of emotion regulation difficulties DERS-16 X X X
Somatic complaints/side effects Body system questions X X X
Gastrointestinal symptoms Bristol Stool Scale X X X X
Self-rating of perceived stress PSS X X X
Major stressors X X X
Blood pressure, pulse rate, height, weight,
waist, hip, medical history, medication evaluation
Assessed by clinician X X X
Physical activity Actigraphy; mobile health application X X
Blood biomarkers Blood sample X X X
Microbiome Stool sample X X X
DNA and RNA Blood sample X X X
Neurocognitive measures CPT-II X X X
Nutritional intake Food diary X X X
Treatment adherence/satisfaction/beliefs
Probabilistic Medication Adherence Scale ProMAS X X X
Abbreviations: ADHD attention-deficit/hyperactivity disorder, ADHD-RS Attention-Deficit/Hyperactivity Disorder Rating Scale, ARI-S Affective Reactivity Index–Self-
Report, BPD borderline personality disorder, CGI-I Clinical Global Impression–Improvement Scale, CGI-S Clinical Global Impression–Severity Scale, CPT-II Continuous
Performance Test, DERS-16 Difficulties in Emotion Regulation Scale, DIVA 2.0 Diagnostic Interview for Adult ADHD, Second Edition, FAST Functioning Assessment
Short Test, IQ intelligence quotient, M.I.N.I.-Plus Mini-International Neuropsychiatric Interview, PROBIA Treatment of impulsivity in adults with probiotics, ProMAS
Probabilistic Medication Adherence Scale, PSS Perceived Stress Scale, SCID-II Structured Clinical Interview for DSM-IV Axis II Disorders, SDQ Strengths and
Difficulties Questionnaire, SES socioeconomic status, UPPS-P Urgency, Premeditation (lack of), Perseverance (lack of), Sensation Seeking, Positive Urgency,
Impulsive Behavior Scale, WAIS Wechsler Adult Intelligence Scale, Y-BOCS Yale-Brown Obsessive Compulsive Scale
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the follow-up (T3) assessment will take place (duration,
approximately 20 min).
Criteria for discontinuing allocated interventions
Any undesirable experience (of either a physical or psy-
chological nature) occurring to a participant during the
study, whether or not considered related to undergoing
treatment with SF or placebo, will be considered an ad-
verse event (AE). Participants will be asked for AEs at
each visit and then will be discussed with the study
physician at the site. Thus, if an AE occurs in response
to SF or placebo, this will immediately be recorded by
the principal investigator (PI) or the PI’s staff, and the
participant may be discontinued from the study.
Serious adverse events (SAEs), serious adverse reac-
tions (SARs) or unexpected serious adverse reactions are
defined, respectively, as any adverse event, reaction, or
unexpected adverse reaction that results in death; is life-
threatening and/or requires hospitalization or prolonga-
tion of existing hospitalization; results in persistent or
significant disability or incapacity; or consists of a con-
genital anomaly or birth defect. Any of them will be
communicated immediately to the lead coordinator of
the trial at Vall d’Hebron Research Institute (VHIR)
and to the coordinating PI at the clinical site, who will
be responsible for reporting the event to the ethics
committee that approved the protocol. Suspected unex-
pected serious adverse reactions (SUSARs) that are fatal
or life-threatening must also be reported not later than
7 days after the sponsor is first made aware of the reac-
tion. Any additional relevant information must be re-
ported within 8 days. SUSARs that are not fatal or life-
threatening must be reported within 15 days of the
sponsor first becoming aware of the reaction. All on-
going AEs will be followed up until no more signs and
symptoms are verifiable or until stability has been
reached. Depending on the event, additional tests or
medical procedures, as well as referrals to a general
physician or a medical specialist, will be indicated dur-
ing this follow-up phase.
In the case that a participant’s psychological state dete-
riorates to a clinically significant degree during the trial,
the investigators will either discuss with the participant
the possibility of withdrawing from the study or decide
that the participant should withdraw. If a participant, for
any reason, requires treatment with certain therapeutic
agents (i.e., antibiotics), the agent taken and time of
administration will be noted. If any other protocol exclu-
sion violation has occurred, the participant’s involve-
ment will be discontinued. Participants may at any time
request to be withdrawn from the study or revoke their
consent to participate. If a patient is discontinued from
the trial, a follow-up visit will be carried out to ensure
the well-being of the participant.
Data management
Participants and clinical staff will be able to fill out all
requested questionnaires online via the Castor database
system (http://castoredc.com/). Then, data will be dir-
ectly uploaded to a central database using a macro soft-
ware. Both the Castor database system and macro
software are fully secure and in accordance with current
standards (i.e., Good Clinical Practice [GCP], 21 CFR
Part 11, EU Data Protection Directive, ISO27001 and
ISO9001 hosting). Both systems are also approved by
the Clinical Research Centre Nijmegen, Nijmegen, The
Netherlands, because it will be responsible for tracking
any changes made manually to raw data. Any other data
will be uploaded (after site-specific quality control) by
the research team to the central database using
encrypted mass storage devices. All information col-
lected in the study will be coded with a unique pseudo-
code identifier (PSC) in such a way that participants
cannot be identified from the corresponding data (dir-
ective 95/46/EC) and ensuring that the information col-
lected for the study remains strictly confidential.
Likewise, collected samples of biomaterial (i.e., blood
and microbiota) will be labeled with the corresponding
PSC. All patient-related data will be stored at the clinical
sites in a database with password protection. A separate
single database on the central server of VHIR will link
the PSC to the participant’s personal data (including
name, address, telephone details, and date of birth). Da-
tabases will be accessible only to the immediate research
team at each site.
Study monitoring
Proper conduct of data collection in the trial will be moni-
tored via on-site visits of a monitoring staff member
throughout the study; quality of data collected will further
be monitored regularly by a statistical supervision team.
After the first five participants per site are included, the
quality of data (on item/trial level) per participant will be
checked, aiming at detecting any error that may occur in
the beginning of the project and to prevent these errors
from recurring. After including participant numbers 5 to
10, the completeness and accuracy of the data on sum-
mary/scale level will be checked for all participants.
Thereafter, data on a summary/scale level will be checked
randomly for 1 in 5 participants. Outcomes of this data
check will be written in an overview and reported to all re-
search personnel. If adjustments to the database or proce-
dures need to be made, these will be made as soon as
possible. Moreover, the investigators will permit quality
data checks, audits, and inspections by providing the
sponsor direct access to source data and other documents
(e.g., medical files) by request.
In each participating center, the PI will be responsible
for the local ethics application, on-site training of
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clinicians, identification and recruitment of participants
including randomization, data collection according to
the study protocol, completion of the case report forms
including answering queries, maintaining and updating
the investigator site file, participation in monitoring, and
reporting SAEs to the study PI in Barcelona. Each site
will have regular meetings with their clinical team in
order to ensure progress of the trial. As the leading co-
ordinator center and with the aim of monitoring the
study progress, the VHIR team will arrange telephone
meetings with the local sites throughout the project on a
regular basis.
Due to the need for research groups to share their data
to maximize the value of each research contribution, to
pool them to address research questions that require lar-
ger numbers, or to carry out meta-analyses, participants
and, if applicable, their legal guardians will be asked
whether they consent that their data (or portions of their
data) will be shared in anonymized fashion with other
research projects.
Statistical analysis
Primary outcome measures will be analyzed by applying
logistic regression analyses with type of treatment, diag-
nostic group (e.g., ADHD, BPD, or both), gender, and
center as independent variables. A sample size of 180
participants will allow for detection of an odds ratio of
2.55 with 90% power, assuming a response rate of 20%
for the CG at a significance level of 0.05. For simplifica-
tion purposes, calculations will assume no effects of the
covariates on the response rate. Secondary analyses will
be performed on the secondary outcome measures
assessed at the different time points. General linear
models will be applied to examine effects of treatment
group on continuous outcome variables while control-
ling for baseline assessment, gender, diagnostic group,
and center. Categorical outcome measures will be inves-
tigated using generalized linear models. Treatment ef-
fects and their 95% confidence intervals will be reported.
To investigate potential long-term effects of probiotics,
data of the EG for 10 weeks will be analyzed. General
linear models for repeated measurements will be applied
to study changes from baseline to follow-up visit for this
group, and missing data will be handled by the last ob-
servation carried forward method. Statistical significance
will be defined at the 0.05 level.
Once the primary and secondary outcome measures re-
sults are obtained, all responsible investigators at all study
sites will get access to the data to be able to reanalyze the
data regarding specific additional research questions.
In case of an external request for replication, the re-
spective statistical analysis will be provided by the trial
statistician.
Ethics and dissemination
Before the first subject is enrolled in the trial, all ethical
and legal requirements will be met. The study protocol,
participant information, and the respective consent form
will be approved according to the respective local and
national regulations at each of the participating centers
before the start of the trial, and participants will be made
aware of the investigational nature and the core aspects
of the study as well. This study will be conducted in ac-
cordance with the principles of the Declaration of
Helsinki (2008) and the Medical Research Involving Hu-
man Subjects Act (WMO). It will follow the principles
of the Guideline for Good Clinical Practice (ICH GCP
guideline E6), EU Directive 2001/20/EC, and applicable
regulatory requirements and guidelines in the participat-
ing countries/regions. The handling of personal data will
be done in accordance with the new General Data Pro-
tection Regulation that started in May 2018 in the Euro-
pean Union.
Trial findings will be reported to public and private
healthcare providers, specific stakeholders such as policy
makers, the medical community, or academic and com-
mercial parties interested in therapy development, as
well as the general public via publications, conferences,
press releases, public talks, and the internet- (e.g., You-
Tube, Facebook, Twitter). All trial results will be re-
ported in accordance with the Consolidated Standards of
Reporting Trials (CONSORT) guidelines (www.consort-
statement.org).
Discussion
We have presented a design and protocol for an RCT of
a nonpharmacological intervention—synbiotic treat-
ment—for the reduction of impulsive and compulsive
symptomatology in a sample of adult patients with
ADHD and/or BPD. The PROBIA study is the first
multinational RCT evaluating the effects of probiotics
on cognitive function, impulsivity, and compulsivity in a
large ADHD and/or BPD sample. Existing studies primar-
ily addressing the effects of supplementation with probio-
tics in psychiatric disorders mostly come from animal
studies or have been done in smaller samples. Moreover,
to date, no RCT has evaluated the composition of gut
microbiota in ADHD and/or BPD populations with a large
sample size. Thus, whether the microbial community in
these individuals is different from that in mentally healthy
humans remains unknown.
Our study will also allow us to identify links between the
microbiome and hallmark characteristics of ADHD and/or
BPD patients (e.g., impulsivity, compulsivity, or aggressive
behavior) and also to investigate whether dietary patterns
and probiotics can induce alterations in the gut microbiota,
which may mediate/moderate effects on these behaviors.
Linking these data with blood biomarkers as well as genetic
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and epigenetic parameters will provide integrated mechan-
istic knowledge on diet/lifestyle–gut–brain–behavior rela-
tionships relevant to impulsivity and compulsivity. In order
to create a study sample population that is highly represen-
tative of impulsivity, broad inclusion criteria will be ap-
plied, with most psychiatric comorbidities being accepted,
allowing us to provide a better illustration of possible ef-
fects that could be expected if the intervention were intro-
duced in a clinical setting. Understanding the microbiota
would be important both for better comprehension of the
biological bases that underlie the studied disorders and for
the future development of new evidenced-based medica-
tions for these conditions.
Trial status
This trial is registered with ClinicalTrials.gov
(NCT03495375) and was first posted on 12 April 2018.
The first participant gave consent on 22 February 2019
and was randomized on 27 February 2019. Recruitment
is expected to be completed 1 April 2021. The most re-
cent version of the protocol (V2.0) was approved by the
Ethical Committee of the University Hospital Vall
d’Hebron, Barcelona, Spain, on 12 April 2019 [PR
(AG)311-2018].
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